Highlights

  • Fiscal 2027 second quarter revenue rose 18% to $928.0 million, with subscription revenue up 16% to $766.8 million.
  • GAAP net income grew to $273.4 million, or $1.66 per diluted share, from $200.3 million, or $1.19.
  • Veeva repurchased about $467 million of stock in six months, and cash plus short-term investments totaled $7.2 billion.
  • Management raised fiscal 2027 revenue guidance to $3,682 million to $3,687 million on its August 26 earnings call.

Veeva Systems (NYSE:VEEV) shares were trading near their 52-week high at USD 317.59 on October 21, 2026, down 0.34%. The life sciences software provider bought Ostro in March, filed its fiscal 2027 second quarter report on August 27, and raised its full-year outlook on a call the day before.

Based in Pleasanton, California, Veeva is a Delaware corporation that calls itself the leading provider of industry cloud solutions for the global life sciences industry. Its applications, agents, data and consulting span four product categories: Development Cloud, Quality Cloud, Commercial Cloud and Data Cloud. For reporting, it groups them into Commercial Solutions and R&D and Quality Solutions, which together served 1,552 customers at January 31, 2026. Its fiscal year ends January 31.

Revenue Up 18% as Operating Income Climbs

Revenue for the quarter ended July 31, 2026 was $928.0 million versus $789.1 million a year earlier. Subscription revenue rose 16% to $766.8 million, with $68 million of the increase from R&D and Quality Solutions and $40 million from Commercial Solutions, which the company tied to wider use by existing customers and annual price adjustments. Professional services and other revenue grew 24% to $161.2 million on implementation and consulting work. Gross margin held at 75%.

GAAP operating income was $275.0 million against $195.9 million. Research and development rose 16% to $222.9 million and sales and marketing 16% to $126.7 million, while general and administrative expense fell 26% to $71.3 million because the prior-year quarter included $31 million of litigation settlement charges. Net income was $273.4 million, or $1.66 per diluted share, compared with $200.3 million, or $1.19. The effective tax rate was 21.8% versus 24.5%. Non-GAAP operating income was $416 million, as cited by management on the call.

For six months, revenue was $1.81 billion, up 17%, net income was $534.4 million, or $3.22 per diluted share, and operating cash flow was $1.37 billion versus $1.12 billion.

Acquisition, Buyback and Balance Sheet

On March 9, 2026, Veeva acquired Rise Healthcare Tech, known as Ostro, for total consideration of $90 million, or $70 million net of cash acquired. Ostro provides an AI-driven chat platform that gives patients and doctors compliant answers. On the call, management called the quarter its best CRM quarter ever and described a selective approach to acquisitions.

In January 2026 the board authorized a share repurchase program of up to $2 billion with a two-year term. Veeva repurchased and retired 2,663,443 shares for about $467 million in the six months. Cash, cash equivalents and short-term investments totaled $7.2 billion at July 31, of which $102 million of cash was held outside the United States. Deferred revenue was $1.31 billion, down from $1.49 billion at January 31. The company said it was not party to any legal proceedings it expects to be material.

Raised Guidance and Product Transition

On the August 26 call, management said it was raising full-year guidance again. The transcript gives fiscal 2027 revenue of $3,682 million to $3,687 million, non-GAAP earnings per share of about $9.21 and third quarter revenue of $932 million to $935 million. The chief financial officer said the shift from legacy R&D products to newer areas such as EDC and Safety does not line up evenly, and that this timing is reflected in the full-year guide. He declined to give guidance beyond the current year. Management also highlighted AI-related work, including Veeva Falcon. The 10-Q warns that revenue from R&D and Quality Solutions is expected to rise as a share of the total. These are company estimates, not guarantees.